A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation
Clinical trial NCT06949761 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06949761
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-06-01
- Primary completion
- 2026-09-01
- Enrollment
- 240
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.